Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for ...

Success in this area means ensuring the right therapy reaches the patient in a form that is stable, effective, and ready for ...

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...

Called enpatoran, the agent targets the Toll-like receptor (TLR) species 7 and 8. Some 50%-60% of patients with systemic ...

We outline what pentadecanoic acid is, how it benefits the body, and my personal experience trying it as a dietary supplement ...

U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for ...

The global softgel capsules market is estimated to be valued at USD 1,245.3 million in 2025 and is projected to reach USD 2,209.2 million by 2035, registering a compound annual growth rate (CAGR) of 5 ...

LIKMEZ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia ...

Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

Compounded semaglutide and tirzepatide are untested and unregulated. Here’s what to discuss with your provider about taking these weight loss drugs.